Portfolio Companies

Research     view all

Alphatec Completes its Senior Leadership Team with Appointment of Brian Snider, Executive Vice President, Strategic Marketing and Product Development

March 24, 2017

 Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced today the addition of two new executives with proven track records in the spine industry, naming Brian Snider as Executive Vice President, Strategic Marketing and Product Development, and Chris Ryan as Area Vice President of Sales in the U.S. Central Region.  Drawing on their deep commercial spine experience, Mr. Snider and Mr. Ryan will focus on building brand awareness with surgeon customers and driving market demand for Alphatec's differentiated product solutions. 

Musculoskeletal News Roundup 23-March-17

March 23, 2017

Alphatec reports earnings...Alphatec, Helius Medical Technologies, Invuity, Micro C, Merit Medical Systems, RadiAction Medical, Vertiflex funding updates...Integra LifeSciences, Sussex Wire acquisition updates...India's National Pharmaceutical Pricing Authority announces regulatory update...Lima Corporate, Medtronic collaboration updates...Bioventus, NuVasive, Spinal Elements, Spineway clinical updates...Safe Orthopaedics, Spinal Simplicity appointment updates

Alphatec Holdings Announces $18.9 Million Private Placement

March 23, 2017

Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, announced  that it has entered into a definitive securities purchase agreement to raise approximately $18.9 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock.

We have invested in more companies in the orthopedic sector than any dedicated healthcare investment firm.
Our team has long standing experience in global markets including active involvement in the rapidly developing Chinese market.
Our teams of musculoskeletal scientific and clinical advisors actively support sourcing and qualifying new technologies and services.
We have key relationships with active strategic acquirers at the CEO level.
Our quest is to find innovative and exciting, emerging and established companies that would benefit from focus, mentorship and investment.
We align our interests with our partners to accelerate growth and create significant value.